Bill Haney, Skyhawk CEO (Dave Pedley/Getty Images for SXSW)
Bill Haney's latest startup scores deal from Sanofi, its newest Big Pharma partner, with $54M upfront
A heavily financed biotech looking to drug RNA with small molecules is adding yet another company to its Big Pharma shortlist.
Skyhawk Therapeutics, the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.